Table 1. Ongoing trials integrating immunotherapy in the therapeutic management of locally advanced NSCLC.
| Study | Number | Phase | Immunotherapy | Institution | Estimated completion date |
|---|---|---|---|---|---|
| Cisplatin and etoposide plus radiation followed by nivolumab/placebo for locally advanced NSCLC (RTOG 3505) | NCT02768558 | III | Anti-PD-1, adjuvant | RTOG Foundation | October 2024 |
| Nivolumab combination with standard first-line chemotherapy and radiotherapy in locally advanced stage IIIA/B non-small cell lung carcinoma (NICOLAS) | NCT02434081 | II | Anti-PD-1, concurrent | European Thoracic Oncology Platform | August 2020 |
| Pembrolizumab in combination with radiotherapy in locally advanced non-small cell lung cancer (NSCLC) (PARIS) | NCT03245177 | I | Anti-PD-1, concurrent and adjuvant | The Christie NHS Foundation Trust | November 2020 |
| Pembrolizumab, paclitaxel, carboplatin, and radiation therapy in treating patients with stage II-IIIB non-small cell lung cancer | NCT02621398 | I | Anti-PD-1, concurrent, adjuvant | Rutgers, The State University of New Jersey | September 2019 |
| DETERRED: MPDL3280A with chemoradiation for lung cancer | NCT02525757 | II | Anti-PD-L1, adjuvant | M.D. Anderson Cancer Center | January 2020 |
| Atezolizumab immunotherapy in patients with advanced NSCLC | NCT03102242 | II | Neo-adjuvant, adjuvant anti PD-L1 | Alliance Foundation Trials | March 2020 |
| Consolidation pembrolizumab following chemoradiation in patients with inoperable/unrespectable stage III NSCLC | NCT02343952 | II | Anti-PD-1, adjuvant | Hoosier Cancer Research Network | December 2018 |
| BLP25 liposome vaccine and bevacizumab after chemotherapy and radiation therapy in treating patients with newly diagnosed stage IIIA or stage IIIB non-small cell lung cancer that cannot be removed by surgery | NCT00828009 | II | Vaccine | Eastern Cooperative Oncology Group | May 2017 |
| Neoadjuvant immunoradiation for resectable non-small cell lung cancer | NCT03237377 | II | Anti-PD-L1 concurrent and anti-PD-L1 and anti-CTLA-4, concurrent | Sidney Kimmel Comprehensive Cancer Center | September 2020 |
| Neoadjuvant chemoradiation plus pembrolizumab followed by consolidation pembrolizumab in NSCLC | NCT02987998 | I | Anti-PD-1, neoadjuvant and adjuvant | Case Comprehensive Cancer Center | January 2020 |
| Neoadjuvant pembrolizumab | NCT02818920 | II | Anti-PD-1, neoadjuvant | Merck Sharp & Dohme | January 2027 |
NSCLC, non-small cell lung cancer; RTOG, Radiation Therapy Oncology Group; PD-1, programmed death 1; PD-L1, programmed death-ligand 1; CTLA-4, cytotoxic T-lymphocyte-associated protein 4; NHS, National Health System.